The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...

Edwards Lifesciences Corp.’s Sapien 3 platform has been approved for a new indication. The Food and Drug Administration ...

The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve replacement (TAVR) therapy, for patients with severe aortic stenosis without ...

With a market cap of $44.3 billion, Edwards Lifesciences Corporation (EW) provides products and technologies to treat ...

A transcatheter aortic valve replacement platform was approved for severe asymptomatic aortic stenosis. Edwards Lifesciences’ TAVR platform is the first to be approved in this population.

For patients with asymptomatic severe aortic stenosis, transcatheter aortic valve replacement was superior to clinical ...

Nitinol innovation in cardiac medtech is not slowing down in 2025, with innovative devices and systems hitting milestones and ...

The US Food and Drugs Administration ( FDA) has approved the Sapien 3 transcatheter aortic valve replacement (TAVR) system for use in patients with severe aortic stenosis who are asymptomatic.

After a trial shows early intervention prevents hospitalization, the US Food and Drug Administration approves transcatheter ...